共 50 条
- [41] Long-term Follow-up and Factors Associated with Active Surveillance Failure for Patients with Non-muscle-invasive Bladder Cancer: The Bladder Cancer Italian Active Surveillance (BIAS) Experience EUROPEAN UROLOGY ONCOLOGY, 2022, 5 (02): : 251 - 255
- [42] Efficacy of hyperthermic intravesical chemotherapy (HIVEC) in patients with non-muscle invasive bladder cancer after BCG failure World Journal of Urology, 2023, 41 : 3195 - 3203
- [44] LONG-TERM SURVIVAL OUTCOMES WITH INTRAVESICAL DOCETAXEL IN THE MANAGEMENT OF NON-MUSCLE-INVASIVE BLADDER CANCER (NMIBC) REFRACTORY TO BCG THERAPY JOURNAL OF UROLOGY, 2012, 187 (04): : E677 - E677
- [45] Long-term Follow-up After En Bloc Transurethral Resection of Non-muscle-invasive Bladder Cancer: Results from a Single-center Experience EUROPEAN UROLOGY OPEN SCIENCE, 2021, 26 : 64 - 71
- [46] Sequential Gemcitabine plus Docetaxel Is the Standard Second-line Intravesical Therapy for BCG-unresponsive Non-muscle-invasive bladder cancer: Pro EUROPEAN UROLOGY FOCUS, 2022, 8 (04): : 1117 - 1120
- [48] Carcinogenesis and Bacillus Calmette-Guerin (BCG) Intravesical Treatment of Non-Muscle-Invasive Bladder Cancer under Tryptophan and Thymine Supplementation NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL, 2021, 73 (11-12): : 2687 - 2694